Abeona Therapeutics stock plummets after revenue recognition issues

NEW YORK, Sept. 3, 2026 /CourierPR/ -- Investors in Abeona Therapeutics Inc. (NASDAQ: ABEO) are being advised to take notice after the company issued a press release detailing financial results and treatment updates for its one-time therapy ZEVASKYN (prademagene zamikeracel). According to a press release, Abeona reported that only four out of five patients treated with the therapy were recognized for revenue, due to one batch failing to meet the minimum number of sheets required for revenue recognition.

Following this news, Abeona's stock price dropped sharply by $1.12 per share, or 14.95%, closing at $6.35 per share on August 13, 2026. In response, Pomerantz Law Firm, a leading firm in corporate, securities, and antitrust class litigation, is now investigating whether Abeona and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.

Pomerantz Law Firm, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, was founded by the late Abraham L. Pomerantz and is recognized for its pioneering work in securities class actions. The firm continues to fight for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct, having recovered numerous multimillion-dollar damages awards.

Attorney advertising. Prior results do not guarantee similar outcomes.